Losartan Potassium
Product Images NDC 16590-952

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 16590-952). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Losartan 100mg Label)

Losartan Potassium 100 mg tablet label by STAT Rx USA LLC. The label indicates 30 tablets in the package. It states the product is generic for Cozaar and includes the NDC number 16590-952-30. It also lists manufacturer Torrent Pharma Inc., Kalamazoo, MI. A warning section notes possible side effects such as dizziness, dry mouth, and muscle cramps.*

FDA Label Image

Structural Formula (Losartanpotassiumusp Figure 01)

Chemical structure of losartan potassium, depicting the molecular arrangement including a chlorinated pyrimidine ring, hydroxymethyl group, biphenyl moiety, and the potassium ion.*

FDA Label Image

Image (Losartanpotassiumusp Figure 02)

A line graph comparing the percentage of patients with primary endpoints over study months for Atenolol and Losartan Potassium Tablets. The x-axis represents study duration in months (0 to 66), and the y-axis shows the percentage of patients affected (0 to 16%). The graph illustrates a lower percentage for Losartan Potassium Tablets compared to Atenolol, with an adjusted risk reduction of 13%, p=0.021.*

FDA Label Image

Image (Losartanpotassiumusp Figure 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 study months for Losartan Potassium Tablets versus Atenolol. The graph shows a lower percentage of patients affected in the Losartan group compared to Atenolol, with an adjusted risk reduction of 25% and a p-value of 0.001.*

FDA Label Image

Image (Losartanpotassiumusp Figure 04)

A forest plot figure titled 'Primary Endpoint Events within Demographic Subgroups,' comparing hazard ratios for 'Primary Composite' and 'Stroke (Fatal/Non-fatal)' events between Losartan Potassium Tablets and Atenolol. The chart includes subgroup data by overall results, age, gender, race, ISH, diabetes, and history of cardiovascular disease with event rates and 95% confidence intervals displayed as squares and diamonds along a horizontal hazard ratio axis.*

FDA Label Image

Image (Losartanpotassiumusp Figure 05)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium Tablets and placebo groups. The y-axis shows % patients with event, and the x-axis shows time in months. The graph indicates a risk reduction of 16.1% with Losartan Potassium Tablets versus placebo.*

FDA Label Image

Logo Image (Losartanpotassiumusp Figure 07)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.